| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | Hercules Offshore Inc | 165,000 | 4,366,000 | 1.55% | ||
| 52 | EXELIXIS INC | 350,000 | 4,477,000 | 1.59% | ||
| 53 | GLAUKOS CORP | 120,000 | 4,529,000 | 1.61% | ||
| 54 | MERCK & CO INC | 75,000 | 4,681,000 | 1.66% | ||
| 55 | GILEAD SCIENCES INC | 60,000 | 4,747,000 | 1.69% | ||
| 56 | DERMIRA INC COM | 150,000 | 5,073,000 | 1.80% | ||
| 57 | ALNYLAM PHARMACEUTICALS INC | 75,000 | 5,083,000 | 1.81% | ||
| 58 | MAZOR ROBOTICS LTD | 200,000 | 5,174,000 | 1.84% | ||
| 59 | AERIE PHARMACEUTICALS INC COM | 165,000 | 6,227,000 | 2.21% | ||
| 60 | NUVASIVE INC | 100,000 | 6,666,000 | 2.37% | ||
| 61 | GLOBAL BLOOD THERAPEUTICS INCORPORATED | 325,000 | 7,491,000 | 2.66% | ||
| 62 | MEDICINES CO | 200,000 | 7,548,000 | 2.68% | ||
| 63 | CELGENE CORP | 75,000 | 7,839,000 | 2.79% | Call | |
| 64 | CELGENE CORP | 75,000 | 7,840,000 | 2.79% | ||
| 65 | ONCOMED PHARMACEUTICALS INC COM | 725,000 | 8,287,000 | 2.95% | ||
| 66 | PFIZER INC | 250,000 | 8,468,000 | 3.01% | ||
| 67 | GW PHARMACEUTICALS PLC | 65,000 | 8,627,000 | 3.07% | Put | |
| 68 | AMGEN INC | 55,000 | 9,175,000 | 3.26% | ||
| 69 | ALEXION PHARMACEUTIC | 75,000 | 9,191,000 | 3.27% | ||
| 70 | ZIMMER BIOMET HLDGS INC | 85,000 | 11,052,000 | 3.93% | ||
| 71 | CLOVIS ONCOLOGY INC | 325,000 | 11,716,000 | 4.16% | ||
| 72 | SHIRE PLC | 65,000 | 12,601,000 | 4.48% | ||
| 73 | BIOGEN INC | 45,000 | 14,086,000 | 5.01% | ||
| 74 | ULTRAGENYX PHARMACEUTICAL INC COM | 200,000 | 14,188,000 | 5.04% |
Portfolio data is normalized using SEC Form 13F filings, including the Restatement filing (0001597549-16-000024, filed 2016.11.17). Although 0001597549-16-000024 is marked by the manager as a New Holdings filing, our automated system processes it as a Restatement filing.
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
